COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

  • End date
    May 1, 2022
  • participants needed
  • sponsor
    OncoImmune, Inc.
Updated on 17 June 2020


The study is designed to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19.  The investigational medication is called CD24Fc.

Participants will be randomly assigned to one of two treatment "arms" for the study and neither the participant, nor the study team will know which arm each participant is assigned to.
- Arm A: CD24Fc / Best Available Treatment
- Arm B: placebo / Best Available Treatment 

CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1 of the study. Total of 230 subjects will be enrolled; half will receive CD24Fc and half will receive placebo. All subjects will be treated with the best available treatment. The follow up period is 28 days.

Condition Coronavirus, COVID-19, *Corona Virus, Covid-19
Treatment Placebo, CD24Fc
Clinical Study IdentifierNCT04317040
SponsorOncoImmune, Inc.
Last Modified on17 June 2020


Yes No Not Sure

Inclusion Criteria

Should be at least 18 years of age
Male or female
Diagnosed with COVID-19 and confirmed SARS-coV-2 viral infection
Able to sign the consent form
Severe COVID-19 (Appendix A), or NIAID 8-point ordinal score 3 to 4 (requiring non-invasive ventilation or oxygen, a SpO2 </= 94% or tachypnea (respiratory rate >/= 24 breaths/min), Appendix B)

Exclusion Criteria

Patients with COVID 19 in critical condition or ARDS (Appendix A) or NIAID 8-point ordinal score 2 (Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO))
Patients with bacterial / fungal infections
Patients who are pregnant, breastfeeding, or have a positive pregnancy test result before enrollment
Severe liver damage (Child-Pugh score C, AST> 5 times the upper limit)
Patients with known severe renal impairment (creatinine clearance 30 mL / min) or patients receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis
The investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note